These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29306457)

  • 21. PCSK9 Inhibitors and Cardiovascular Disease: Impact on Cardiovascular Outcomes.
    Farmaki P; Damaskos C; Garmpis N; Garmpi A; Savvanis S; Diamantis E
    Curr Drug Discov Technol; 2020; 17(2):138-146. PubMed ID: 30526464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
    Wagner M; Lindgren P; Merikle E; Goetghebeur M; Jönsson B
    Can J Cardiol; 2009 Nov; 25(11):e362-9. PubMed ID: 19898698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
    Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
    Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
    Achimastos A; Alexandrides T; Alexopoulos D; Athyros V; Bargiota A; Bilianou E; Chrysochoou C; Drogari E; Elisaf M; Ganotakis E; Goudevenos I; Ioannidis I; Kolovou G; Kotsis V; Lekakis I; Liberopoulos E; Melidonis A; Nikolaou V; Ntaios G; Papanas N; Pappas S; Pitsavos C; Rallidis L; Richter D; Skoumas I; Tentolouris N; Tousoulis D; Tselepis A; Tsioufis K; Tziakas D; Tziomalos K; Vardas P; Vlachopoulos C; Vlahakos D
    Hormones (Athens); 2016; 15(1):8-14. PubMed ID: 27086681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.
    Shah P
    Curr Cardiol Rep; 2018 May; 20(7):51. PubMed ID: 29779055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?
    Arbel R; Hammerman A; Triki N; Greenberg D
    Int J Cardiol; 2016 Oct; 220():242-5. PubMed ID: 27389448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
    Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
    Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC;
    Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
    Gupta S
    Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.
    Athyros VG; Tziomalos K; Doumas M; Sfikas G; Karagiannis A
    Curr Pharm Des; 2017; 23(10):1477-1483. PubMed ID: 28128061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective.
    Ademi Z; Zomer E; Tonkin A; Liew D
    Int J Cardiol; 2018 Nov; 270():54-59. PubMed ID: 30220379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors.
    Blumenthal DM; Goldman D; Jena AB
    JAMA Cardiol; 2017 Oct; 2(10):1063-1064. PubMed ID: 28854318
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.
    Michaeli DT; Michaeli JC; Boch T; Michaeli T
    Cardiovasc Drugs Ther; 2023 Aug; 37(4):683-694. PubMed ID: 35015186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
    Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S
    Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.